1. Home
  2. EML vs TTRX Comparison

EML vs TTRX Comparison

Compare EML & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eastern Company (The)

EML

Eastern Company (The)

HOLD

Current Price

$20.51

Market Cap

119.2M

ML Signal

HOLD

TTRX

Turn Therapeutics Inc.

N/A

Current Price

$3.65

Market Cap

116.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
EML
TTRX
Founded
1858
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
119.2M
116.0M
IPO Year
1995
N/A

Fundamental Metrics

Financial Performance
Metric
EML
TTRX
Price
$20.51
$3.65
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$8.00
AVG Volume (30 Days)
15.9K
14.4K
Earning Date
06-22-2026
01-01-0001
Dividend Yield
2.10%
N/A
EPS Growth
185.40
N/A
EPS
1.17
N/A
Revenue
$248,970,345.00
N/A
Revenue This Year
$19.05
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$17.89
N/A
Revenue Growth
N/A
N/A
52 Week Low
$17.61
$2.57
52 Week High
$26.78
$5.98

Technical Indicators

Market Signals
Indicator
EML
TTRX
Relative Strength Index (RSI) 65.31 50.93
Support Level $17.96 $3.55
Resistance Level $20.93 $4.01
Average True Range (ATR) 0.66 0.21
MACD 0.26 0.05
Stochastic Oscillator 77.30 51.47

Price Performance

Historical Comparison
EML
TTRX

About EML Eastern Company (The)

The Eastern Co manages industrial businesses that design, manufacture, and sell engineered solutions to industrial markets. The company manages the financial, operational, and strategic performance of its businesses to increase cash generation, operating earnings, and long-term shareholder value. It operates in the United States and Other Countries and generates the majority of its revenue from the United States.

About TTRX Turn Therapeutics Inc.

Turn Therapeutics Inc is a clinical-stage biotechnology company focused on developing pharmaceutical and medical device products for dermatology, wound care, and infectious disease. The company's proprietary platform technology, called PermaFusion, enhances drug performance by improving the stability and bioavailability of active pharmaceutical ingredients, which allows for reduced doses and fewer side effects. Its primary development programs target skin conditions such as moderate to severe eczema and onychomycosis.

Share on Social Networks: